The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation

Ophthalmic Surg Lasers Imaging. 2010 Mar-Apr;41(2):190-5. doi: 10.3928/15428877-20100303-06.


Background and objective: To report the development of subretinal fibrosis after the injection of intravitreal bevacizumab in eyes with proliferative diabetic retinopathy (PDR) refractory to panretinal laser photocoagulation (PRP).

Patients and methods: Twenty-one eyes of 15 patients treated with PRP and intravitreal injection of bevacizumab were included in this study. The clinical outcomes of 21 eyes having subretinal fibrosis after intravitreal bevacizumab injection were reviewed.

Results: There were 9 men and 6 women with a mean age of 51.3 +/- 8.9 years. All eyes had PDR refractory to panretinal photocoagulation and were treated with at least one intravitreal injection of 1.25 mg of bevacizumab (mean number of injections: 1.8). Before injection, there was subretinal fibrosis in 5 eyes and vitreoretinal traction in 19 eyes. After a mean follow-up period of 7 months, the development or progression of subretinal fibrosis was detected in all eyes.

Conclusion: Intravitreal injection of bevacizumab may cause formation or progression of subretinal fibrosis in patients with PDR refractory to PRP.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Diabetic Retinopathy / diagnosis
  • Diabetic Retinopathy / therapy*
  • Disease Progression
  • Female
  • Fibrosis
  • Follow-Up Studies
  • Humans
  • Injections
  • Laser Coagulation / methods*
  • Male
  • Middle Aged
  • Prognosis
  • Retina / drug effects
  • Retina / pathology*
  • Retina / surgery
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitreoretinopathy, Proliferative / chemically induced*
  • Vitreoretinopathy, Proliferative / pathology
  • Vitreous Body


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab